We are glad inform you about a recent publication to further support the usefulness of mucoprotection in the relief of symptoms and in the prevention of recurrences in uncomplicated UTIs
The trial "Xyloglucan + Gelose Combination versus Placebo as Adjuvant Therapy to First-Line Antimicrobials for Uncomplicated Urinary Tract Infection in Adults" has been published on Urologia Internationalis.
In the study, safety and efficacy of a Xyloglucan based medical device were investigated as adjuvant therapy to first-line antimicrobials for treatment of uncomplicated UTIs in adults.
In this multicentre, randomised, parallel group, double-blind clinical trial, the medical device or the placebo were administered orally in combination with an antimicrobial agent twice a day for 5 days, then alone once a day for 5 days; beginning on Day 30 of the study the medical device or the placebo were administered alone once a day for 15 days per month for 2 months.
Frequency of adverse events (AEs) was much lower in the medical device group vs the placebo group (5% and 45%, respectively).
The xyloglucan based medical device reduced the presence of uropathogenic bacteria in 100% of patients at Day 11, with recurrence in 3 patients (15%) by Day 76. In the placebo group there were still 55% uroculture positive patients at Day 11, with recurrence in 14 patients (70%) by Day 76.
Moreover, in the group treated with the xyloglucan based medical device there was a significant reduction of urinary incontinence and urgency of micturition compared with placebo, with symptom resolution in all patients by Day 90.
CONCLUSIONS: The xyloglucan based medical device was safe, well tolerated, and it reduced bacteriological and symptomatic parameters in patients with uncomplicated UTI.
This study provides the evidence that orally administered Xyloglucan, in combination with antibiotics, is effective in controlling acute UTIs symptomatology and that cycles of treatment with xyloglucan orally administered can reduce the recurrence rate in UTI patients.
In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.